[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569395":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":18,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":18,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Metastatic Cancer","Participants will have 24\u002F7 access to the ApricityCare service. Participants can check in and report any symptoms or side effects through the ApricityCare app, or by phone, at any time.\n\nParticipants will be asked to report your status at least weekly, even if participants are not experiencing any side effects. ApricityCare nurses will review each participants report and provide appropriate education and\u002For virtual management or escalate, as needed, to the study doctor or emergency service, based on guidelines. Each encounter with an ApricityCare nurse will be sent to the electronic health record (EHR) in real time for review\u002Finclusion into your medical record.\n\nFor any in-person visits participants attend, the study doctor will review the ApricityCare symptom summary with participants. For all these visits, please bring your smartphone, which carries the ApricityCare application, for this review.",[12],"Behavioral: Metastatic Cancer",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"BEHAVIORAL","Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Bilal A Siddiqui, MD","CONTACT","(713) 563-4600","basiddiqui@mdanderson.org",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-95.36327,29.76328,{"lat":38,"lon":37},[41],{"name":21,"role":22,"phone":42,"phoneExt":18,"email":24},"713-563-4600",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100569395","a-study-of-the-apricitycare-program-for-early-detection-and-management-of-treatment-related-adverse-events-in-patients-with-cancer-100569395",false,"NCT06693687","A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer","Inclusion Criteria:\n\n* Age 18 years of age or older\n* Confirmed diagnosis of cancer\n\n  * Part 1 (Run-in Phase): Only patients with prostate, kidney, and\u002For bladder cancer will be enrolled with either localized or metastatic disease.\n  * Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4.\n* Planned to receive systemic anti-cancer therapy\n* Ability to understand and the willingness to sign a written informed consent document\n* Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese\n* Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF\n\nExclusion Criteria:\n\n\\- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).","ALL","18 Years",{"count":54,"type":55},425,"ESTIMATED","INTERVENTIONAL",[58],"NA","To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare.\n\nInvestigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.",[9],"2026-07-14",{"date":63,"type":64},"2026-07-16","ACTUAL",{"date":66,"type":64},"2024-12-18",{"date":68,"type":55},"2027-11-01",{"name":5,"class":6},1]